BMY Mezigdomide PDUFA May 2027: 52% PFS Risk Reduction

Bristol Myers Squibb (BMY) closed July 28 at $62.56, down from a 52-week high near $73. The stock trades at a $126.8 billion market cap with a forward P/E of 9.6x. That compressed multiple tells you what the market thinks of BMS right now: Revlimid is declining, Opdivo faces biosimilar entry from July 2026, and the pipeline needs to deliver. The mezigdomide NDA acceptance is part of the answer. Whether it is a good answer depends on whether two CELMoD drugs can share one franchise.

The FDA accepted the NDA for mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) on July 13, 2026, with a PDUFA date of May 13, 2027. The filing rests on SUCCESSOR-2 (NCT05552976), a Phase 3 trial presented as a late-breaking oral at ASCO 2026 and published in The Lancet. This is the second CELMoD NDA from BMS in 2026. Iberdomide, the first, has a PDUFA of August 17, 2026. Mezigdomide follows nine months later.

The Trial: SUCCESSOR-2

SUCCESSOR-2 randomized 479 patients 3:2 to MeziKd (mezigdomide 1.0 mg, carfilzomib 56 mg/m2, dexamethasone 40 mg) versus Kd alone. The patient population is the hard end of myeloma: median 2 prior lines, 92.1% triple-class exposed, 85.8% refractory to anti-CD38 antibodies, 75.8% refractory to lenalidomide. These are the patients running out of options.

The primary endpoint hit hard. Median PFS was 18.0 months for MeziKd versus 8.3 months for Kd (HR 0.48, 95% CI 0.36-0.63, p<0.0001). A 52% reduction in the risk of disease progression or death. The effect was consistent across all prespecified subgroups regardless of prior therapy, age, refractory status, cytogenetic risk, or extramedullary disease.

Secondary endpoints reinforced the primary:

• ORR: 80.2% vs 53.4%. Very good partial response or better: 60.1% vs 30.9%. Complete response or better: 26.7% vs 8.9%.
• Duration of response: 12-month DOR rate 72% vs 54%.
• PFS2 (time to second progression): median 23.6 vs 13.0 months (HR 0.53, 95% CI 0.39-0.72).
• OS: immature at cutoff. Deaths in 21.5% (MeziKd) vs 26.7% (Kd), HR 0.79 (95% CI 0.54-1.15). No crossover of curves, but not statistically significant.

On safety, Grade 3/4 hematologic events included thrombocytopenia (39.2%) and anemia (26.0%). Grade 5 treatment-emergent adverse events occurred in 7.3% of MeziKd patients versus 4.3% for Kd, the majority in the context of myeloma progression.

The PFS doubling is real. The Lancet publication and ASCO late-breaking designation confirm the academic community considers this a top-tier data set. But the OS data is not yet mature, and the Grade 5 TEAE rate is higher with MeziKd. The FDA will weigh the PFS strength against the safety signal, but oncology approvals on PFS alone are well-precedented when the effect size is this large.

The Competitive Picture: Two CELMoDs, One Pipeline

BMS is running two CELMoD programs in parallel. Iberdomide (PDUFA August 17, 2026) pairs with daratumumab and dexamethasone (IberDd). Mezigdomide (PDUFA May 13, 2027) pairs with carfilzomib and dexamethasone (MeziKd). Both are oral cereblon E3 ligase modulators that degrade Ikaros and Aiolos transcription factors. The mechanism is the same; the molecular optimization differs.

Mezigdomide is engineered for more rapid and maximal degradation than iberdomide. Whether that translates to superior clinical outcomes is an open question. There are no head-to-head trials. The two drugs target different relapsed myeloma populations: iberdomide with anti-CD38 therapy, mezigdomide with proteasome inhibition. BMS has said both drugs have a place in the treatment picture, with different pairing partners. That is convenient for a company that needs two approvals, but investors should ask whether two CELMoDs in the same indication is a franchise or a redundancy.

The broader myeloma competitive dynamics are intense. J&J’s Carvykti (BCMA CAR-T) generated $963 million in 2024 and is accelerating toward $2B annually. BMS’s own Abecma CAR-T is the underdog. Bispecifics from J&J (Tecvayli), Pfizer (Elrexfio), and Regeneron (linvoseltamab) are all chasing the same relapsed patients. For more on the bispecific-CAR-T rivalry, our coverage of the J&J Tecvayli/Talvey Monumental-6 Phase 3 readout breaks down how bispecifics are reshaping the post-CAR-T setting.

Mezigdomide is oral. That matters. Community oncology practices without CAR-T or bispecific infrastructure can prescribe an oral drug. In the SUCCESSOR-2 population, 37.2% had been exposed to pomalidomide and 7.3% to anti-BCMA therapy. Mezigdomide works after prior IMiD exposure, which is critical because Revlimid generic erosion means more patients are lenalidomide-refractory earlier in their treatment journey.

Valuation: The Revlimid Replacement Math

BMS needs mezigdomide to work for financial reasons that go beyond the clinical data. Revlimid generated $5.77 billion in 2024, declining at 5-8% annually as generics erode the franchise. Pomalyst contributed roughly $2.5 billion. Combined, these IMiDs are a $8+ billion franchise in decline. The CELMoDs are the replacement.

Analyst estimates for iberdomide peak sales range from $5-6 billion (Seeking Alpha). Mezigdomide estimates are more conservative at $3-4 billion. If both drugs reach the midpoint of those ranges, BMS replaces the Revlimid+Pomalyst revenue stream with two new oral drugs. That is the bull case: the CELMoD platform is a self-renewing franchise.

The multiple myeloma market was estimated at $21.3 billion across the 7MM in 2023. If mezigdomide captures 10% of a growing market, that is $2-3 billion in peak sales. At a 4x peak sales multiple for a late-stage oncology asset, the NPV is $8-12 billion discounted over 5 years to peak. Against BMS’s $126.8 billion market cap, that is 6-9% of enterprise value. Material, but not transformative.

Compare this to a pure-play myeloma company where a single drug drives the entire valuation. Our Gilead anito-cel BCMA CAR-T PDUFA analysis shows how Gilead paid $7.8B for a single asset. BMS is building from within, which is cheaper but slower. The risk is that iberdomide and mezigdomide cannibalize each other rather than expanding the addressable market. If physicians pick one CELMoD and stick with it, BMS has two drugs competing for the same prescriptions.

Risks

1. OS immaturity. The PFS benefit is strong, but OS data is not yet statistically significant (HR 0.79, p=NS). If the final OS analysis fails to confirm a survival benefit, the label and uptake will suffer. The FDA may approve on PFS, but payers and oncologists increasingly demand OS evidence.

2. Iberdomide sequencing. If iberdomide is approved in August 2026 and gains traction, physicians may adopt it as the default CELMoD before mezigdomide launches in May 2027. Mezigdomide would then enter as a second CELMoD in a market that already has one. Differentiation on degradation kinetics is a molecular argument, not a clinical one. Without head-to-head data, the commercial case for two CELMoDs is weak.

3. Safety signal. The 7.3% Grade 5 TEAE rate, while partly driven by myeloma progression, is higher than the 4.3% control arm. Thrombocytopenia at 39.2% and anemia at 26.0% are manageable but real. In heavily pretreated patients, cumulative toxicity matters.

4. Competitive compression. CAR-T and bispecifics are moving into earlier lines. If the treatment approach shifts toward cell therapy before the MeziKd launch, the addressable population for an oral triplet in late relapse shrinks. The myeloma treatment algorithm is evolving faster than any single drug’s development timeline.

The Verdict

Mezigdomide’s SUCCESSOR-2 data is genuinely impressive. An 18.0-month median PFS in a population where the control arm manages 8.3 months is a clinically meaningful result. The 52% risk reduction, consistent across subgroups, published in The Lancet and late-breaking at ASCO, gives the FDA a strong basis for approval on May 13, 2027. I expect approval.

But the investment case is not about whether mezigdomide gets approved. It is about whether BMS can turn two CELMoD approvals into a franchise that replaces $8+ billion in declining IMiD revenue. At $62.56 and 9.6x forward earnings, BMS is priced for modest pipeline success, not transformation. Mezigdomide at $3-4 billion peak sales plus iberdomide at $5-6 billion gets you there, but only if both drugs launch successfully and do not cannibalize each other.

I am cautiously positive on the May 13, 2027 PDUFA. The data supports approval. But BMS is a Hold, not a Buy, until iberdomide’s August 17 PDUFA clarifies whether the market wants one CELMoD or two. For a purer play on myeloma innovation, investors should watch the CAR-T and bispecific companies where a single approval moves the stock. BMS processes these catalysts with the weight of a $127 billion ship: the direction changes, but the speed does not.

For our broader FDA catalyst tracking, the Q3 2026 FDA calendar covers the iberdomide August 17 PDUFA alongside other upcoming decisions. Our guide to trading FDA catalysts explains why mega-cap pharma catalysts like this one are low-volatility events compared to small-cap binary PDUFA plays.